Vivli is pleased to announce that Steven E. Kern, PhD, will serve as the new Chair of its Board of Directors succeeding Michael Stebbins. Dr. Kern has been a valued member of Vivli’s Board and brings more than three decades of experience spanning academia, global health, and the pharmaceutical industry.

Dr. Kern most recently served as Executive Director of Global Health Labs, a Gates Ventures initiative focused on developing diagnostic and healthcare technologies for low- and middle-income countries. Prior to that, he was Deputy Director of Quantitative Sciences at the Bill & Melinda Gates Foundation. His academic career included nearly 15 years as Associate Professor of Pharmaceutics, Anesthesiology, and Bioengineering at the University of Utah, where he led clinical pharmacology research across diverse populations ranging from preterm infants to elderly adults.

Dr. Kern has long been an advocate for open, accessible research data and brings deep expertise in data-driven drug development and global health innovation. As Board Chair, he will help guide Vivli’s continued growth as a global leader in clinical research data sharing.

“Steve has been a tremendous asset to Vivli’s Board, and we are delighted that he will now serve as our next Chair,” said Rebecca Li, CEO of Vivli. “His experience across global health, pharmaceutical research, and data science aligns closely with Vivli’s mission. We look forward to working closely with him as we expand access to data and enable new scientific insights worldwide.”